Gerald is a serial diluted - sad but true. You simply can not tell your shareholders that you are creating shareholder value and appreciation while more than doubling the float each and every year - and not providing revenue simultaneously. It's like speaking out of both side of your mouth. That said, I hope Gerald lands size able and sustaining revenue on LymPro soon.